Adults with overweight or obesity who received once-weekly ecnoglutide, a novel GLP-1 receptor agonist, had superior and ...

With semaglutide and tirzepatide dosed once weekly, their estimated average yearly costs in the U.S. are $14,080 and $8,126, ...

Approximately 15 million Americans are on a GPL-1 or better known as Ozempic, Wegovy and Zepbound but there will be upcoming ...

An investigational, oral small-molecule GLP-1 receptor agonist improved glycated hemoglobin levels in adults with early-stage ...

More than 90% of patients achieved clinically meaningful weight reduction compared to placebo in a phase 3 trial of ecnoglutide.

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who ...

That is according to the findings of a study presented on Friday at the European Academy of Neurology congress. The pilot ...

Novo Nordisk rebounds from 2024 lows as GLP-1 supply issues ease, partnerships expand, and valuation turns attractive. Find ...

Glucagon-Like-Peptide-1 Agonists, like Ozempic, have become extremely popular for weight loss. Here are some of the side ...

Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of ...

In a move that could reshape how doctors approach both weight and heart health, the American College of Cardiology (ACC) ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.